https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/IRD/opus-genetics-fda-approval-phentolamine-presbyopia BiopharmaWatch en 2026-10-16T16:00:00.000Z Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-3-data-cystectomy-avoidance BiopharmaWatch en 2026-10-16T15:49:00.000Z ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors https://www.biopharmawatch.com/news/MBRX/moleculin-announces-reverse-stock-split-20261016 BiopharmaWatch en 2026-10-16T13:20:00.000Z Moleculin Announces Reverse Stock Split https://www.biopharmawatch.com/news/REVB/revelation-biosciences-reverse-stock-split-october-2026 BiopharmaWatch en 2026-10-16T13:00:00.000Z Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 https://www.biopharmawatch.com/news/NTHI/neonc-neo100-child-improvement-compassionate-use BiopharmaWatch en 2026-10-16T12:56:00.000Z NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone https://www.biopharmawatch.com/news/GEHC/ge-healthcare-end-tidal-control-software-study BiopharmaWatch en 2026-10-16T12:47:00.000Z Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow https://www.biopharmawatch.com/news/IART/integra-lifesciences-ent-technologies-aao-hnsf-2026 BiopharmaWatch en 2026-10-16T12:39:00.000Z Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting https://www.biopharmawatch.com/news/PPCB/propanc-prp-chemotherapy-resistant-pancreatic-cancer BiopharmaWatch en 2026-10-16T12:36:00.000Z Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-real-world-evidence-cah BiopharmaWatch en 2026-10-16T12:30:00.000Z Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-eanm-2026-atnm-400-presentations BiopharmaWatch en 2026-10-16T12:30:00.000Z Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-pre-esmo-panel-weei-inhibition BiopharmaWatch en 2026-10-16T12:30:00.000Z Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology https://www.biopharmawatch.com/news/ASND/transcon-cnp-positive-chmp-opinion-achondroplasia BiopharmaWatch en 2026-10-16T12:29:00.000Z Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children https://www.biopharmawatch.com/news/BMRA/biomerica-first-quarter-fiscal-2027-results BiopharmaWatch en 2026-10-16T12:19:00.000Z Biomerica Reports First Quarter Fiscal 2027 Financial Results https://www.biopharmawatch.com/news/RPRX/royalty-pharma-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-16T12:02:30.000Z Royalty Pharma declares fourth quarter 2026 dividend https://www.biopharmawatch.com/news/NTHI/neonc-reports-clinical-improvement-child-treated-neo100 BiopharmaWatch en 2026-10-16T12:00:32.000Z NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-reverse-stock-split BiopharmaWatch en 2026-10-16T12:00:00.000Z Azitra, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/CRIS/curis-announces-private-placement-85-million-funding BiopharmaWatch en 2026-10-16T12:00:00.000Z Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-closing-4-0-million-financing-through-private BiopharmaWatch en 2026-10-16T12:00:00.000Z Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-cfo-retirement-richard-lindahl BiopharmaWatch en 2026-10-16T11:50:00.000Z Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl https://www.biopharmawatch.com/news/ALEC/alector-pricing-underwritten-offering BiopharmaWatch en 2026-10-16T11:30:00.000Z Alector Announces Pricing of Underwritten Offering https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-sean-maenpaa-appointment BiopharmaWatch en 2026-10-16T11:30:00.000Z Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-appoints-tammi-gaskins-ceo BiopharmaWatch en 2026-10-16T11:30:00.000Z Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer https://www.biopharmawatch.com/news/OGN/organon-positive-interim-phase-3-results-miu-della BiopharmaWatch en 2026-10-16T11:30:00.000Z Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261016 BiopharmaWatch en 2026-10-16T11:30:00.000Z BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/REGN/libtayo-eu-approval-chmp-dosing-regimen BiopharmaWatch en 2026-10-16T11:00:00.000Z Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types https://www.biopharmawatch.com/news/TLSA/tiziana-doses-last-patient-phase-2-trial-alzheimers BiopharmaWatch en 2026-10-16T11:00:00.000Z Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-appoints-david-rubenstein-chief-scientist BiopharmaWatch en 2026-10-16T11:00:00.000Z Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis https://www.biopharmawatch.com/news/GUTS/fractyl-health-revita-remains-1-study-results BiopharmaWatch en 2026-10-16T11:00:00.000Z Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-vopimetostat-esmo-2026 BiopharmaWatch en 2026-10-16T11:00:00.000Z Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/IONS/tryngolza-olezarsen-eu-approval-recommendation BiopharmaWatch en 2026-10-16T10:45:00.000Z TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG) https://www.biopharmawatch.com/news/JNJ/chmp-recommends-approval-talvey-daratumumab-multiple-myeloma BiopharmaWatch en 2026-10-16T10:31:00.000Z CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma https://www.biopharmawatch.com/news/HIT/health-in-tech-annual-meeting-2026 BiopharmaWatch en 2026-10-16T10:30:00.000Z Health In Tech to Host Annual Meeting of Stockholders https://www.biopharmawatch.com/news/OMER/omeros-chmp-negative-opinion-narsoplimab-ta-tma BiopharmaWatch en 2026-10-16T10:19:00.000Z Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-first-patient-eb103-star-light-1 BiopharmaWatch en 2026-10-15T22:45:00.000Z Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase https://www.biopharmawatch.com/news/QDEL/quidelortho-inducement-grants-nasdaq-listing-rule BiopharmaWatch en 2026-10-15T22:10:00.000Z QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NRC/nrc-health-research-patient-feedback-action BiopharmaWatch en 2026-10-15T20:53:00.000Z New NRC Health Research Reveals What Sets High-Performing Health Systems Apart: Turning Patient Feedback Into Action https://www.biopharmawatch.com/news/MDT/medtronic-best-inventions-2026-stealth-axis-corsano BiopharmaWatch en 2026-10-15T20:30:00.000Z Medtronic Named to TIME Best Inventions of 2026 List for Stealth AXiS™ surgical system and Corsano™* multi-parameter wearable https://www.biopharmawatch.com/news/CNXU/conexeu-sciences-5-million-private-placement BiopharmaWatch en 2026-10-15T20:30:00.000Z Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors https://www.biopharmawatch.com/news/FRNM/freenome-report-q3-2026-financial-results BiopharmaWatch en 2026-10-15T20:29:00.000Z Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/ARDT/ardent-health-q3-2026-results-conference-call BiopharmaWatch en 2026-10-15T20:15:00.000Z Ardent Health Announces Third Quarter 2026 Results Conference Call and Webcast Date https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-clinical-pipeline-ascend-trial BiopharmaWatch en 2026-10-15T20:15:00.000Z Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001 https://www.biopharmawatch.com/news/MMED/minimed-board-of-directors-independent-company BiopharmaWatch en 2026-10-15T20:10:00.000Z MiniMed Announces Board of Directors for its Next Chapter as an Independent Company https://www.biopharmawatch.com/news/LFST/lifestance-q3-2026-earnings-call BiopharmaWatch en 2026-10-15T20:10:00.000Z LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026 https://www.biopharmawatch.com/news/WRBY/warby-parker-q3-2026-results-announcement BiopharmaWatch en 2026-10-15T20:05:00.000Z Warby Parker to Announce Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/FLGT/fulgent-announces-q3-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/EXEL/exelixis-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/GILD/gilead-sciences-q3-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-craig-hallum-conference-2026 BiopharmaWatch en 2026-10-15T20:05:00.000Z Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference https://www.biopharmawatch.com/news/MGNX/macrogenics-first-patient-dosed-mgc030-phase-1-study BiopharmaWatch en 2026-10-15T20:05:00.000Z MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-inducement-awards-nasdaq-listing-rule-5635-20261015 BiopharmaWatch en 2026-10-15T20:05:00.000Z Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MOBI/mobia-medical-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/SOLV/solventum-third-quarter-earnings-november-2026 BiopharmaWatch en 2026-10-15T20:05:00.000Z Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026 https://www.biopharmawatch.com/news/SI/shoulder-innovations-q3-2026-financial-results BiopharmaWatch en 2026-10-15T20:05:00.000Z Shoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-investor-events-2026 BiopharmaWatch en 2026-10-15T20:05:00.000Z LB Pharmaceuticals to Participate in Upcoming Investor Events https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q3-2026-financial-results-release BiopharmaWatch en 2026-10-15T20:05:00.000Z Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-15T20:05:00.000Z Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-10-15T20:01:00.000Z Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/GH/twinstrand-biosciences-patent-upheld-guardant-health BiopharmaWatch en 2026-10-15T20:01:00.000Z TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent https://www.biopharmawatch.com/news/CDNA/caredx-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T20:01:00.000Z CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/SNDX/syndax-revuforj-time-best-inventions-2026 BiopharmaWatch en 2026-10-15T20:01:00.000Z Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List https://www.biopharmawatch.com/news/BIIB/biogen-q3-2026-research-development-charges BiopharmaWatch en 2026-10-15T20:00:00.000Z Biogen Preliminary Third Quarter 2026 Acquired In-Process Research and Development Charges https://www.biopharmawatch.com/news/AVXL/anavex-fda-clearance-blarcamesine-fragile-x-syndrome BiopharmaWatch en 2026-10-15T20:00:00.000Z Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome https://www.biopharmawatch.com/news/MDXH/mdxhealth-q3-2026-revenue-guidance-suspension BiopharmaWatch en 2026-10-15T20:00:00.000Z MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance https://www.biopharmawatch.com/news/IRD/opus-genetics-opgx-best1-opgx-lca5-retina-rio-2026 BiopharmaWatch en 2026-10-15T20:00:00.000Z Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026 https://www.biopharmawatch.com/news/MDLN/medline-new-distribution-center-van-buren-township BiopharmaWatch en 2026-10-15T18:17:00.000Z Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich. https://www.biopharmawatch.com/news/ENSG/ensign-group-class-action-lawsuit BiopharmaWatch en 2026-10-15T17:35:00.000Z Shareholders who lost money in shares of acquired The Ensign Group, Inc. (NASDAQ: ENSG) should contact Wolf Haldenstein Immediately https://www.biopharmawatch.com/news/INGN/inogen-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T17:00:00.000Z Inogen to Report Third Quarter 2026 Financial Results on November 5, 2026 https://www.biopharmawatch.com/news/NTRA/natera-signatera-mrd-test-time-best-inventions-2026 BiopharmaWatch en 2026-10-15T16:46:00.000Z Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026 https://www.biopharmawatch.com/news/MDT/medtronic-separation-minimed-group BiopharmaWatch en 2026-10-15T14:00:00.000Z Medtronic Completes Separation of MiniMed Group, Inc. https://www.biopharmawatch.com/news/LLY/lilly-third-quarter-2026-financial-results-call BiopharmaWatch en 2026-10-15T14:00:00.000Z Lilly confirms date and conference call for third-quarter 2026 financial results announcement https://www.biopharmawatch.com/news/MMED/minimed-completes-separation-from-medtronic BiopharmaWatch en 2026-10-15T14:00:00.000Z MiniMed Completes Separation from Medtronic https://www.biopharmawatch.com/news/RVMD/rasonque-positive-chmp-opinion-pancreatic-cancer BiopharmaWatch en 2026-10-15T13:45:00.000Z Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-ceo-adc-payload-strategy BiopharmaWatch en 2026-10-15T13:20:00.000Z Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner https://www.biopharmawatch.com/news/NRXS/neuraxis-medical-policy-coverage-expansion BiopharmaWatch en 2026-10-15T13:18:00.000Z NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives https://www.biopharmawatch.com/news/CODX/co-diagnostics-pcr-platform-plague-detection BiopharmaWatch en 2026-10-15T13:15:00.000Z Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection https://www.biopharmawatch.com/news/EDSA/edesa-biotech-fda-ind-clearance-phase-2-vitiligo-study BiopharmaWatch en 2026-10-15T13:15:00.000Z Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study https://www.biopharmawatch.com/news/LEXX/lexaria-animal-study-glp-1-a26-1-results BiopharmaWatch en 2026-10-15T13:13:06.000Z Lexaria Announces Results from Animal Study GLP-1-A26-1 https://www.biopharmawatch.com/news/CVS/cvs-health-midlife-collective-collaboration BiopharmaWatch en 2026-10-15T13:00:00.000Z CVS Health collaborates with The Midlife Collective to redefine a woman's midlife health journey https://www.biopharmawatch.com/news/NTHI/uae-banking-heavyweight-joins-neonc-brain-cancer-drug-development BiopharmaWatch en 2026-10-15T12:57:00.000Z UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-first-patient-dosed-car-t-study BiopharmaWatch en 2026-10-15T12:46:00.000Z Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma https://www.biopharmawatch.com/news/RXRX/recursion-sanofi-first-in-class-immunology-candidate BiopharmaWatch en 2026-10-15T12:45:00.000Z Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration https://www.biopharmawatch.com/news/ONMD/onemednet-expands-hospital-network-12-hospitals BiopharmaWatch en 2026-10-15T12:45:00.000Z OneMedNet Adds Leading Hospital System Provider Network, Expanding By Up to 12 Hospitals https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-acquires-minority-stake-sod-sciences BiopharmaWatch en 2026-10-15T12:45:00.000Z Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q3-2026-financial-results-call BiopharmaWatch en 2026-10-15T12:32:00.000Z Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/BEAT/heartbeam-joins-exit-cvd-consortium-ecg-monitoring BiopharmaWatch en 2026-10-15T12:31:00.000Z HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients https://www.biopharmawatch.com/news/RXRX/recursion-pricing-200-million-offering-class-a-stock BiopharmaWatch en 2026-10-15T12:30:00.000Z Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-eanm-2026-atnm-400-study BiopharmaWatch en 2026-10-15T12:30:00.000Z Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer https://www.biopharmawatch.com/news/CAI/caris-life-sciences-third-quarter-2026-results BiopharmaWatch en 2026-10-15T12:30:00.000Z Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/PYPD/polypid-virtual-investor-day-october-2026 BiopharmaWatch en 2026-10-15T12:30:00.000Z PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026 https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-fda-labeling-review-ketamine BiopharmaWatch en 2026-10-15T12:27:00.000Z NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine https://www.biopharmawatch.com/news/RXRX/recursion-200-million-offering-clinical-updates-partnership BiopharmaWatch en 2026-10-15T12:22:00.000Z Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone https://www.biopharmawatch.com/news/DRMA/dermata-positive-results-tome-treatment BiopharmaWatch en 2026-10-15T12:05:00.000Z Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment https://www.biopharmawatch.com/news/GH/guardant-health-blood-test-colorectal-cancer-screening BiopharmaWatch en 2026-10-15T12:05:00.000Z Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests https://www.biopharmawatch.com/news/NTHI/neonc-ceo-address-global-health-summit-2026 BiopharmaWatch en 2026-10-15T12:00:48.000Z NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026 https://www.biopharmawatch.com/news/LLY/omvoh-achieves-corticosteroid-free-remission BiopharmaWatch en 2026-10-15T12:00:00.000Z New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year https://www.biopharmawatch.com/news/XERS/xeris-biopharma-leadership-endocrinology-data-disclosures BiopharmaWatch en 2026-10-15T12:00:00.000Z Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-q3-2026-financial-results BiopharmaWatch en 2026-10-15T12:00:00.000Z Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 https://www.biopharmawatch.com/news/GEHC/ge-healthcare-mini-trace-magni-ce-mark-copper-64 BiopharmaWatch en 2026-10-15T12:00:00.000Z GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68 https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-cypath-lung-chest-2026 BiopharmaWatch en 2026-10-15T12:00:00.000Z bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026 https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-conference-call-q3-2026-results BiopharmaWatch en 2026-10-15T12:00:00.000Z Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-third-quarter-2026-results BiopharmaWatch en 2026-10-15T12:00:00.000Z PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026 https://www.biopharmawatch.com/news/HUMA/humacyte-commercial-update-symvess-adoption BiopharmaWatch en 2026-10-15T12:00:00.000Z Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals https://www.biopharmawatch.com/news/TARA/protara-therapeutics-thrive-3-trial-enrollment-completed BiopharmaWatch en 2026-10-15T12:00:00.000Z Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-private-placement-200-million BiopharmaWatch en 2026-10-15T12:00:00.000Z First Tracks Biotherapeutics Announces $200 Million Private Placement https://www.biopharmawatch.com/news/IRLA/irulya-therapeutics-craig-hallum-conference-2026 BiopharmaWatch en 2026-10-15T12:00:00.000Z IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference https://www.biopharmawatch.com/news/DXR/daxor-commercial-expansion-blood-volume-diagnostic-platform BiopharmaWatch en 2026-10-15T12:00:00.000Z Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26 https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-phase-2-study-ven-sobafusp-alfa-igan BiopharmaWatch en 2026-10-15T12:00:00.000Z Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-ind-eik1006-prostate-cancer BiopharmaWatch en 2026-10-15T12:00:00.000Z Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer https://www.biopharmawatch.com/news/LEGN/legend-biotech-fda-clearance-lb2501-car-t-therapy BiopharmaWatch en 2026-10-15T12:00:00.000Z Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy https://www.biopharmawatch.com/news/EPRX/eupraxia-reaches-enrollment-target-resolve-trial-eprx BiopharmaWatch en 2026-10-15T12:00:00.000Z Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis https://www.biopharmawatch.com/news/MENS/jyong-biotech-texas-facility-commercialization BiopharmaWatch en 2026-10-15T12:00:00.000Z Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates https://www.biopharmawatch.com/news/NAUT/nautilus-biotechnology-q3-2026-results-announcement BiopharmaWatch en 2026-10-15T12:00:00.000Z Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026 https://www.biopharmawatch.com/news/HELP/helus-pharma-appoints-dr-suresh-durgam-board BiopharmaWatch en 2026-10-15T11:30:09.000Z Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors https://www.biopharmawatch.com/news/LH/labcorp-acquires-bioreference-health-assets BiopharmaWatch en 2026-10-15T11:30:00.000Z Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-appoints-matt-david-cfo BiopharmaWatch en 2026-10-15T11:30:00.000Z Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-phase-3-selva-results-pedra-2026 BiopharmaWatch en 2026-10-15T11:30:00.000Z Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference https://www.biopharmawatch.com/news/SPRC/scisparc-transformation-agentic-ai-technologies BiopharmaWatch en 2026-10-15T11:06:00.000Z SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies https://www.biopharmawatch.com/news/NEO/neogenomics-expands-indica-labs-partnership-ai-pathology BiopharmaWatch en 2026-10-15T11:05:00.000Z NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology https://www.biopharmawatch.com/news/LGND/ligand-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-15T11:00:00.000Z Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026 https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-chardan-healthcare-conference BiopharmaWatch en 2026-10-15T11:00:00.000Z Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q3-2026-financial-results-webcast BiopharmaWatch en 2026-10-15T11:00:00.000Z Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 https://www.biopharmawatch.com/news/INSM/insmed-palm-clinical-development-program-chest-2026 BiopharmaWatch en 2026-10-15T11:00:00.000Z Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026 https://www.biopharmawatch.com/news/KRYS/krystal-biotech-kb113-gorlin-syndrome-results BiopharmaWatch en 2026-10-15T11:00:00.000Z Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome https://www.biopharmawatch.com/news/IMCR/immunocore-phase-1-trial-imc-s118ai-type-1-diabetes BiopharmaWatch en 2026-10-15T11:00:00.000Z Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-phase-2b-clover-wam-results BiopharmaWatch en 2026-10-15T11:00:00.000Z Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-announces-presentations-world-vaccine-congress-europe-2026 BiopharmaWatch en 2026-10-15T11:00:00.000Z Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026 https://www.biopharmawatch.com/news/ADMA/adma-biologics-ivig-manufacturing-process-publication BiopharmaWatch en 2026-10-15T11:00:00.000Z ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process https://www.biopharmawatch.com/news/CRON/cronos-acquires-canadelaar-europe-cannabis-leader BiopharmaWatch en 2026-10-15T11:00:00.000Z Cronos Completes Acquisition of CanAdelaar, Europe’s Largest Adult-Use Cannabis Company https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-fda-anaphylm-nda-resubmission BiopharmaWatch en 2026-10-15T11:00:00.000Z Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-428-idweek-2026 BiopharmaWatch en 2026-10-15T11:00:00.000Z Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 https://www.biopharmawatch.com/news/ANL/adlai-nortye-clinical-collaboration-lilly-merck BiopharmaWatch en 2026-10-15T11:00:00.000Z Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab https://www.biopharmawatch.com/news/PFSA/profusa-receives-iso-13485-certification-gmed BiopharmaWatch en 2026-10-15T10:30:00.000Z Profusa Receives ISO 13485:2016 Certificate from GMED https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q3-2026-results-release BiopharmaWatch en 2026-10-15T10:00:00.000Z Rockwell Medical to Release Third Quarter 2026 Results on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/AZN/insitro-astrazeneca-ai-therapeutics-collaboration BiopharmaWatch en 2026-10-15T10:00:00.000Z insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies https://www.biopharmawatch.com/news/ZYME/zymeworks-participation-investor-conferences-q3-2026-results BiopharmaWatch en 2026-10-15T10:00:00.000Z Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EVO/evotec-appoints-dr-joanna-holbrook-cso BiopharmaWatch en 2026-10-15T06:04:00.000Z Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board https://www.biopharmawatch.com/news/ARGX/argenx-third-quarter-2026-financial-results-update BiopharmaWatch en 2026-10-15T05:00:00.000Z argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 https://www.biopharmawatch.com/news/TAK/takeda-orzeyful-launch-japan-china BiopharmaWatch en 2026-10-15T00:30:00.000Z Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 https://www.biopharmawatch.com/news/DXCM/dexcom-connect-study-type-2-diabetes BiopharmaWatch en 2026-10-14T21:10:00.000Z Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-update-vqw-765-clinical-development BiopharmaWatch en 2026-10-14T21:00:00.000Z Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program https://www.biopharmawatch.com/news/CERS/cerus-corporation-workshop-aabb-annual-meeting-2026 BiopharmaWatch en 2026-10-14T20:30:00.000Z Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting https://www.biopharmawatch.com/news/ELVN/enliven-therapeutics-kristine-ball-appointment-phase-3-trial BiopharmaWatch en 2026-10-14T20:30:00.000Z Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year https://www.biopharmawatch.com/news/CMPX/compass-announces-inducement-grants-nasdaq-listing-rule-5635-c-4 BiopharmaWatch en 2026-10-14T20:30:00.000Z Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CHRS/coherus-oncology-webcast-interim-tagmokitug-data BiopharmaWatch en 2026-10-14T20:30:00.000Z Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026 https://www.biopharmawatch.com/news/IBRX/fda-expands-anktiva-approval-non-muscle-invasive-bladder-cancer BiopharmaWatch en 2026-10-14T20:18:00.000Z FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-activates-intermountain-health-lds-hospital BiopharmaWatch en 2026-10-14T20:15:00.000Z Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/OABI/omniab-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-14T20:05:00.000Z OmniAb to Report Third Quarter 2026 Financial Results on October 30 https://www.biopharmawatch.com/news/TDOC/teladoc-health-third-quarter-2026-results BiopharmaWatch en 2026-10-14T20:05:00.000Z Teladoc Health to Announce Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q3-2026-financial-results BiopharmaWatch en 2026-10-14T20:05:00.000Z Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/RZLT/rezolute-completes-enrollment-phase-3-upLIFT-study-ersodetug BiopharmaWatch en 2026-10-14T20:05:00.000Z Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism https://www.biopharmawatch.com/news/LSTA/lisata-therapeutics-appoints-jeff-farrow-board BiopharmaWatch en 2026-10-14T20:05:00.000Z Lisata Therapeutics Appoints Jeff Farrow to Board of Directors https://www.biopharmawatch.com/news/PACB/pacbio-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-14T20:05:00.000Z PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/LKFT/lakefront-sale-preclinical-car-t-programs BiopharmaWatch en 2026-10-14T20:01:00.000Z Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics https://www.biopharmawatch.com/news/MRVI/maravai-lifesciences-earnings-conference-call-november-2026 BiopharmaWatch en 2026-10-14T20:01:00.000Z Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-14T20:01:00.000Z MannKind to Participate in the Chardan Healthcare Conference https://www.biopharmawatch.com/news/MDXG/mimedx-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-10-14T20:01:00.000Z MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026 https://www.biopharmawatch.com/news/BLTE/belite-bio-tinlarebant-stargardt-disease-submission BiopharmaWatch en 2026-10-14T20:00:00.000Z Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 https://www.biopharmawatch.com/news/ACB/aurora-cannabis-reject-curaleaf-bid BiopharmaWatch en 2026-10-14T19:48:00.000Z Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside